What is Glide Pharmaceutical Technologies?
Glide Pharmaceutical Technologies operates as a specialized product engineering firm, providing comprehensive services that span the entire product lifecycle. From initial embedded hardware design to complex software development and IoT integration, the company serves as a catalyst for innovation. By transforming client concepts into scalable, market-ready products, Glide has established itself as a versatile partner for businesses seeking to enhance their technological footprint. Their service model is uniquely tailored to support high-growth industries, ensuring that clients can effectively navigate the transition from prototype to mass-market adoption with precision and technical rigor.
How much funding has Glide Pharmaceutical Technologies raised?
Glide Pharmaceutical Technologies has raised a total of $4M across 1 funding round:
Private Equity
$4M
Private Equity (2017): $4M with participation from Oxford Capital Partners, Hygea VCT, and Invesco
Key Investors in Glide Pharmaceutical Technologies
Oxford Capital Partners
An investment manager focused on providing growth capital to smaller companies across a range of industries to help entrepreneurs scale their businesses.
Hygea VCT
A venture capital firm specializing in supporting growing businesses through diversified growth capital investments within the UK market.
Invesco
A global, publicly owned investment manager providing comprehensive equity and fixed income portfolios to institutional and retail clients worldwide.
What's next for Glide Pharmaceutical Technologies?
With the successful closure of this major strategic investment, Glide Pharmaceutical Technologies is poised to enter a new phase of enterprise-level scaling. The company's roadmap likely involves the expansion of its engineering teams and the enhancement of its proprietary development frameworks to meet the increasing demand for sophisticated IoT solutions. By leveraging the expertise of its institutional backers, Glide is expected to focus on deepening its penetration into the SaaS and VR markets, where the demand for high-fidelity product engineering remains acute. This strategic pivot will likely prioritize long-term value creation, ensuring that the firm remains at the forefront of the industrial and consumer technology sectors as it continues to refine its service delivery model.
See full Glide Pharmaceutical Technologies company page
